Full-Time

Senior Clinical Trial Associate

Posted on 9/27/2025

HeartFlow

HeartFlow

501-1,000 employees

Non-invasive cardiac imaging to guide treatment

Compensation Overview

$85k - $120k/yr

+ Cash Bonus

California, USA

Hybrid

Hybrid role; on-site in SF Bay Area required.

Category
Biology & Biotech (8)
, , , , , , ,
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Excellent written and oral English skills
  • Strong interpersonal skills
  • Excellent organizational skills
  • Strong attention to detail and excellent follow through on assigned tasks
  • Ability, flexibility, and willingness to learn new things quickly with little direction and/or guidance
  • Ability to work independently as well as part of a project team
  • Strong analytical skills and problem solving abilities
  • Proficiency in Microsoft Office Suite (Word, Excel, PowerPoint) as well as Google Applications
  • Ability to interact professionally both internally and externally
  • Self-starter with the ability to multi-task and prioritize appropriately under pressure
  • Knowledge of ICH-GCP guidelines and FDA regulations preferred
  • BA or BS degree in a science or related field
  • 3+ years demonstrated experience in human clinical research trials, or equivalent
Responsibilities
  • Manage multiple Investigator Initiated Clinical studies, which may include collecting regulatory documents as necessary, assisting with the contracting process between parties, tracking study progress internally and externally, being the main point of contact for external study teams and also internally at HeartFlow, participating in project team meetings, tracking and maintaining all study related information in the central study database and also maintaining accurate and complete files on the clinical drive. Ensure all study files are current and accurate. In addition, collect and organize all ancillary study related data and send for processing internally at HeartFlow as applicable and in compliance with HIPAA privacy laws; provide results back to the study investigators as required.
  • Site management activities for HeartFlow sponsored study sites, which may include helping with potential enrollment issues, answering protocol and EDC related questions, reviewing data to ensure consistency and accuracy, tracking study visit progress, tracking expected payments to be made to the site, maintaining accurate and complete regulatory documentation, provide ongoing training as necessary to new and existing study staff, and additional tasks as required.
  • Conduct study start up activities, which includes reviewing informed consent forms for accuracy and completeness, collecting required regulatory documentation from the site, assisting with IRB submissions, building study binders and miscellaneous study materials, assisting with the contracting process between Sponsor and Study Site, and other tasks as required. Provide day-to-day clinical project support for other research projects, which may include filing and maintaining Clinical Trial Master Files (TMFs), reviewing documents for accuracy, reviewing monitoring reports for completeness and accuracy, developing and updating departmental SOPs as necessary, and documenting and distributing meeting minutes.
  • Manage and track finances against study budgets in accordance with executed study contracts, as well as collect and track invoices from clinical sites, and liaise with the Finance department as necessary.
  • Assist with the development of required Heartflow sponsored study tools and documents, which may include: the testing and development of Electronic Databases, the development of CRFs and Source Documents, the development of logs and forms to be used at study sites, and additional tasks as required.
  • Perform other duties as needed.
Desired Qualifications
  • Knowledge of ICH-GCP guidelines and FDA regulations preferred

HeartFlow provides a non-invasive cardiac test that helps doctors visualize a patient’s coronary arteries to diagnose and plan treatment for heart disease. It uses a proprietary set of analyses—FFRCT Analysis, RoadMap Analysis, Plaque Analysis, and HeartFlow Planner—to create a detailed, patient-specific visualization from imaging data, enabling clinicians to assess blood flow and plaque without surgery. This approach reduces the need for invasive procedures, lowers risk for patients, and can cut costs for healthcare providers. Compared with traditional methods, HeartFlow offers validated, FDA-cleared tools that integrate multiple analyses into one platform, giving physicians a clearer, data-driven basis for diagnosis and treatment decisions. The company’s goal is to improve cardiovascular care by making safer, more efficient diagnosis and treatment planning widely available in hospitals and clinics around the world.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • 2025 revenues hit $176M, up 40%, with 24-26% growth to $218-222M projected 2026.
  • FISH&CHIPS delivers greater-than-modeled cost savings, boosting NHS and payer adoption.
  • Capricorn's $48M stake and Bain's $419M investment signal strong investor confidence.

What critics are saying

  • Ongoing $116.79M 2025 net losses exhaust cash, forcing dilutive financing by 2027.
  • NHS cost scrutiny post-FISH&CHIPS slashes margins on $160.6M US revenues in 2026.
  • Siemens Healthineers AI-CT rivals capture 30% US hospital contracts within 12 months.

What makes HeartFlow unique

  • Lesion-specific FFRCT predicts MI and revascularization strongest in FISH&CHIPS 90,000-patient study.
  • PCI Navigator integrates AI 3D models for pre-procedural stent planning launched October 2025.
  • FFRCT combines anatomy, physiology, plaque analysis in personalized 3D heart models.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Stock Options

401(k) Company Match

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

2%

2 year growth

1%
Yahoo Finance
Mar 23rd, 2026
HeartFlow soars 27% as firm targets 24-26% revenue growth in 2026

Heartflow Inc. surged 27% week-on-week following its strong 2025 performance and optimistic growth guidance. The medical technology company reported 2025 revenues of $176 million, up 40% from $125.8 million in 2024, with US revenues rising 41% to $160.6 million and international revenues climbing 26% to $15.4 million. The company remains unprofitable, posting a net loss of $116.79 million, 21% higher than the previous year. However, fourth-quarter net loss decreased 26% to $24.4 million. For 2026, Heartflow projects revenue growth of 24% to 26%, targeting between $218 million and $222 million. CEO John Farquhar said the guidance "reflects strong business fundamentals" and expressed high confidence in consistent execution.

Yahoo Finance
Mar 22nd, 2026
Capricorn Investment Group buys $48M stake in AI cardiac diagnostics firm HeartFlow

Capricorn Investment Group has purchased 1.7 million shares of HeartFlow, establishing a new position worth $48.18 million in the AI-powered cardiac diagnostics company, according to an SEC filing dated 17 February 2026. The stake represents 5.83% of Capricorn's reportable assets under management. HeartFlow offers AI-driven, non-invasive diagnostic solutions for coronary artery disease, generating revenue from healthcare providers and systems. The company went public in August 2025 and currently has a market capitalisation of $2.22 billion. As of 20 March 2026, HeartFlow shares traded at $26.30, down 10.7% year-to-date from a 52-week high of $41.22 reached last October. The company reported trailing twelve-month revenue of $161.88 million and a net loss of $125.37 million.

Yahoo Finance
Mar 17th, 2026
HeartFlow to report Q4 results with $46.5M revenue expected, analysts cut earnings forecast to -$2.11 per share

HeartFlow Inc is set to report Q4 2025 earnings on 18 March 2026. The consensus estimate projects revenue of $46.50 million and a loss of $0.27 per share. Full-year 2025 revenue is expected to reach $173.36 million, with a loss of $2.11 per share. Over the past 90 days, revenue estimates have increased slightly, whilst earnings estimates have declined. In Q3 2025, HeartFlow beat revenue expectations by 10.29% but missed earnings forecasts, posting a loss of $1.04 per share against an expected loss of $0.32 per share. The stock fell 13.43% following that release. Six analysts have set an average one-year price target of $38.50, suggesting an 83.51% upside from the current price of $20.98. The average brokerage recommendation is "Outperform".

Daily Political
Feb 3rd, 2026
HeartFlow's $317M IPO lock-up period ends tomorrow as analysts set $38.50 target

HeartFlow, a medical technology company developing non-invasive diagnostics for coronary artery disease, will see its lock-up period expire on 4th February. The company issued 16,666,667 shares in its August public offering at $19.00 per share, raising $316.7 million. Following the expiry, restrictions preventing company insiders and major shareholders from selling shares will be lifted. Shares traded at $28.78 on Tuesday, giving the company a market capitalisation of $2.45 billion. HeartFlow has received positive analyst coverage, with five buy ratings, two hold ratings and one sell rating. The consensus price target stands at $38.50. The company's technology uses computational modelling to analyse coronary CT angiography data, creating three-dimensional physiological models to identify coronary lesions without invasive procedures.

The Motley Fool
Nov 30th, 2025
HeartFlow Acquired for $65M by Billionaire

Tulsa-based Schusterman Interests acquired 1.9 million shares of HeartFlow, Inc. for $65 million, making it the fourth-largest holding in their portfolio. HeartFlow, an AI-driven heart diagnostics company, saw its shares rise 70% from its $19 IPO price in August. The acquisition reflects confidence in HeartFlow's technology and potential for revenue growth. As of September 30, HeartFlow represented 14.9% of Schusterman's 13F assets.

INACTIVE